HK1106952A1 - Antibody fragment-targeted immunoliposomes for systemic gene delivery - Google Patents

Antibody fragment-targeted immunoliposomes for systemic gene delivery

Info

Publication number
HK1106952A1
HK1106952A1 HK08100589.9A HK08100589A HK1106952A1 HK 1106952 A1 HK1106952 A1 HK 1106952A1 HK 08100589 A HK08100589 A HK 08100589A HK 1106952 A1 HK1106952 A1 HK 1106952A1
Authority
HK
Hong Kong
Prior art keywords
cancer
antibody fragment
compositions
gene delivery
nucleic acid
Prior art date
Application number
HK08100589.9A
Other languages
English (en)
Inventor
William Alexander
Liang Xu
Cheng-Cheng Huang
Wenhua Tang
Esther H Chang
Original Assignee
Univ Georgetown
Synergene Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Georgetown, Synergene Therapeutics Inc filed Critical Univ Georgetown
Publication of HK1106952A1 publication Critical patent/HK1106952A1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6905—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion
    • A61K47/6911—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion the form being a liposome
    • A61K47/6913—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion the form being a liposome the liposome being modified on its surface by an antibody
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0008—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers
    • A61K9/1272—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers with substantial amounts of non-phosphatidyl, i.e. non-acylglycerophosphate, surfactants as bilayer-forming substances, e.g. cationic lipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2810/00—Vectors comprising a targeting moiety
    • C12N2810/50—Vectors comprising as targeting moiety peptide derived from defined protein
    • C12N2810/80—Vectors comprising as targeting moiety peptide derived from defined protein from vertebrates
    • C12N2810/85—Vectors comprising as targeting moiety peptide derived from defined protein from vertebrates mammalian
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2810/00—Vectors comprising a targeting moiety
    • C12N2810/50—Vectors comprising as targeting moiety peptide derived from defined protein
    • C12N2810/80—Vectors comprising as targeting moiety peptide derived from defined protein from vertebrates
    • C12N2810/85—Vectors comprising as targeting moiety peptide derived from defined protein from vertebrates mammalian
    • C12N2810/859—Vectors comprising as targeting moiety peptide derived from defined protein from vertebrates mammalian from immunoglobulins

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Dispersion Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Virology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
HK08100589.9A 1999-02-22 2008-01-17 Antibody fragment-targeted immunoliposomes for systemic gene delivery HK1106952A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US12113399P 1999-02-22 1999-02-22

Publications (1)

Publication Number Publication Date
HK1106952A1 true HK1106952A1 (en) 2008-03-20

Family

ID=22394769

Family Applications (1)

Application Number Title Priority Date Filing Date
HK08100589.9A HK1106952A1 (en) 1999-02-22 2008-01-17 Antibody fragment-targeted immunoliposomes for systemic gene delivery

Country Status (11)

Country Link
US (3) US7479276B1 (fr)
EP (3) EP1154756B1 (fr)
JP (2) JP4799736B2 (fr)
AT (2) ATE350012T1 (fr)
AU (1) AU3703100A (fr)
CA (1) CA2362550C (fr)
DE (1) DE60032739T2 (fr)
ES (2) ES2278597T3 (fr)
HK (1) HK1106952A1 (fr)
PT (1) PT1811036E (fr)
WO (1) WO2000050008A2 (fr)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9034329B2 (en) 1999-02-22 2015-05-19 Georgetown University Preparation of antibody or an antibody fragment-targeted immunoliposomes for systemic administration of therapeutic or diagnostic agents and uses thereof
US7780882B2 (en) 1999-02-22 2010-08-24 Georgetown University Simplified and improved method for preparing an antibody or an antibody fragment targeted immunoliposome for systemic administration of a therapeutic or diagnostic agent
US8617514B2 (en) 1999-02-22 2013-12-31 Georgetown University Tumor-targeted nanodelivery systems to improve early MRI detection of cancer
DE10061110B4 (de) * 2000-12-07 2006-12-21 Schaller, Gerhard, Prof. Dr. med. Expression der Keratingene 8 und 18 zur Therapie von Tumoren, insbesondere des Mammakarzinoms
EP1408996B1 (fr) * 2001-04-02 2008-09-10 Georgetown University Procede simplifie et ameliore pour preparer les immunoliposomes ou polyplexes diriges par un anticorps ou un fragment d'anticorps pour l'administration systemique d'un agent therapeutique ou diagnostique
EP2075256A2 (fr) 2002-01-14 2009-07-01 William Herman Ligands ciblés
EP1595142A4 (fr) * 2003-01-28 2006-08-23 Univ Georgetown Procede pour l'evaluation de l'efficacite de certains traitements du cancer
CN103251562B (zh) * 2003-06-04 2016-04-27 乔治敦大学 改良脂质体复合物的稳定性和保存期的方法
JP5478886B2 (ja) * 2005-10-20 2014-04-23 ジョージタウン・ユニバーシティ 癌の早期ｍｒｉ検出を改善するための腫瘍標的化ナノ送達系
CA2628300C (fr) 2005-11-02 2018-04-17 Protiva Biotherapeutics, Inc. Molecules d'arnsi modifiees et utilisations de celles-ci
EP2023897A4 (fr) * 2006-05-15 2013-04-03 Univ Georgetown Préparation d'immunoliposomes ciblés sur un anticorps ou sur des fragments d'anticorps, destinée à une administration systémique d'agents thérapeutiques ou diagnostiques et utilisations
JP5890095B2 (ja) 2007-07-09 2016-03-22 ジョージタウン・ユニバーシティＧｅｏｒｇｅｔｏｗｎ Ｕｎｉｖｅｒｓｉｔｙ カチオン性リポソーム媒介核酸送達を用いて免疫応答を引き起こす方法
JP4934531B2 (ja) * 2007-07-11 2012-05-16 株式会社日立製作所 アナログデジタル変換器及びその制御方法並びに無線トランシーバ回路
US20110269942A1 (en) * 2007-08-09 2011-11-03 Daiichi Sankyo Company, Limited Antibodies modified with hydrophobic molecule
US9006191B2 (en) 2007-12-27 2015-04-14 Protiva Biotherapeutics, Inc. Silencing of polo-like kinase expression using interfering RNA
AU2009236219B8 (en) 2008-04-15 2015-06-25 Arbutus Biopharma Corporation Silencing of CSN5 gene expression using interfering RNA
WO2011044545A2 (fr) 2009-10-09 2011-04-14 Sigalov Alexander B Procédés et compositions pour une imagerie ciblée
EP2582387A2 (fr) 2010-06-17 2013-04-24 The United States Of America As Represented By The Secretary, National Institutes Of Health Compositions et procédés pour traiter des affections inflammatoires
BR112013013083A2 (pt) 2010-11-30 2016-12-13 Genentech Inc métodos para transportar um composto, para aumentar exposição do cns a um composto, para diminuir a depuração de um composto, para aumentar a retenção no cns de um composto, para otimizar a farmacocinética, para tratar um distúrbio neurológico em um mamífero, para desenvolver um anticorpo, anticorpo, fragmento de anticorpo, anticorpo multiespecífico e uso de um anticorpo
ES2528472T3 (es) 2011-02-03 2015-02-10 The Government Of The U.S.A, As Represented By The Secretary, Dept. Of Health And Human Services Vacunas multivalentes para el virus de la rabia y filovirus
WO2013075132A1 (fr) 2011-11-17 2013-05-23 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Compositions de commutateurs arn thérapeutiques et procédés d'utilisation
US9035039B2 (en) 2011-12-22 2015-05-19 Protiva Biotherapeutics, Inc. Compositions and methods for silencing SMAD4
IL224860B (en) * 2012-09-19 2019-05-30 Univ Georgetown Methods for preparing targeted liposome complexes and their uses
WO2014046630A1 (fr) 2012-09-19 2014-03-27 Keskin, Dilek Système d'administration de médicament liposomal ciblé contre la tumeur
US20140120157A1 (en) * 2012-09-19 2014-05-01 Georgetown University Targeted liposomes
WO2014046983A1 (fr) 2012-09-21 2014-03-27 Intensity Therapeutic Procédé de traitement du cancer
EP2968598B1 (fr) 2013-03-14 2020-05-27 Georgetown University Traitement après l'exposition à un agent neurotoxique
US10415037B2 (en) 2014-10-02 2019-09-17 Arbutus Biopharma Corporation Compositions and methods for silencing hepatitis B virus gene expression
US10627340B2 (en) 2015-04-09 2020-04-21 Bikanta Corporation Imaging systems and methods using fluorescent nanodiamonds
GB201506870D0 (en) * 2015-04-22 2015-06-03 Ucb Biopharma Sprl Method
US20180245074A1 (en) 2015-06-04 2018-08-30 Protiva Biotherapeutics, Inc. Treating hepatitis b virus infection using crispr
WO2017019891A2 (fr) 2015-07-29 2017-02-02 Protiva Biotherapeutics, Inc. Compositions et méthodes de silençage de l'expression du gène du virus de l'hépatite b
CN109069520A (zh) 2016-02-25 2018-12-21 应用生物实验室公司 保护空气传播的病原体和刺激物的组合物和方法
US20170360815A1 (en) 2016-02-25 2017-12-21 Applied Biological Laboratories, Inc. Compositions and methods for protecting against airborne pathogens and irritants
EP4104854A3 (fr) 2016-04-04 2023-03-08 The United States of America as represented by the Secretary of the Department of Health and Human Services Vaccins multivalents pour le virus de la rage et les coronavirus
JP2020517750A (ja) * 2017-04-19 2020-06-18 エイピーエイ− アドバンスト・テクノロジーズ・リミテッドＡｐａ− Ａｄｖａｎｃｅｄ Ｔｅｃｈｎｏｌｏｇｉｅｓ Ｌｔｄ． 癌処置のための融合性リポソーム、組成物、キットおよびその使用
WO2019032921A1 (fr) * 2017-08-09 2019-02-14 La Jolla Institute For Allergy And Immunology Fonction anti-apoptotique de pkm2 et d'anticorps scfv exprimés de manière intracellulaire
KR102443358B1 (ko) 2017-12-06 2022-09-14 어비디티 바이오사이언시스 인크. 근위축증 및 근긴장성 이영양증을 치료하는 조성물 및 방법
WO2020077039A1 (fr) * 2018-10-12 2020-04-16 Synergene Therapeutics, Inc. Procédés de réduction des effets secondaires de l'immunothérapie
WO2021195469A1 (fr) 2020-03-27 2021-09-30 Avidity Biosciences, Inc. Compositions et procédés de traitement d'une dystrophie musculaire
CN116509818A (zh) * 2023-04-18 2023-08-01 中国人民解放军军事科学院军事医学研究院 一种低毒性的脂溶性纳米粒组合物及其制备方法和应用

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4429008B1 (en) * 1981-12-10 1995-05-16 Univ California Thiol reactive liposomes
US4946778A (en) * 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US5688488A (en) * 1989-04-03 1997-11-18 Purdue Research Foundation Composition and method for tumor imaging
AU642980B2 (en) 1990-03-21 1993-11-04 Quest International B.V. Ultilization of enzymes
US6099842A (en) 1990-12-03 2000-08-08 The United States Of America As Represented By The Department Of Health And Human Services Recombinant immunotoxin composed of a single chain antibody reacting with the human transferrin receptor and diptheria toxin
US5747469A (en) * 1991-03-06 1998-05-05 Board Of Regents, The University Of Texas System Methods and compositions comprising DNA damaging agents and p53
AU6014094A (en) * 1992-12-02 1994-06-22 Baylor College Of Medicine Episomal vectors for gene therapy
US5705655A (en) 1992-12-17 1998-01-06 Megabios Corporation Amphiphilic nitrogen containing imidazolinium derivative compounds and uses
JPH09510601A (ja) * 1993-11-12 1997-10-28 ケース・ウエスタン・リザーブ・ユニバーシティ ヒト遺伝子治療用のエピソーム発現ベクター
US5635380A (en) * 1994-01-18 1997-06-03 Vanderbilt University Enhancement of nucleic acid transfer by coupling virus to nucleic acid via lipids
US5928944A (en) 1994-02-04 1999-07-27 The United States Of America As Represented By The Department Of Health And Human Services Method of adenoviral-medicated cell transfection
WO1995032299A1 (fr) * 1994-05-20 1995-11-30 The Board Of Trustees Of The Leland Stanford Junior University Systeme de replication autonome pour cellules mammaliennes
WO1995035301A1 (fr) 1994-06-22 1995-12-28 Megabios Corporation Amphiphiles cationiques
US5856152A (en) * 1994-10-28 1999-01-05 The Trustees Of The University Of Pennsylvania Hybrid adenovirus-AAV vector and methods of use therefor
US5786214A (en) 1994-12-15 1998-07-28 Spinal Cord Society pH-sensitive immunoliposomes and method of gene delivery to the mammalian central nervous system
FR2730637B1 (fr) * 1995-02-17 1997-03-28 Rhone Poulenc Rorer Sa Composition pharmaceutique contenant des acides nucleiques, et ses utilisations
DE69638269D1 (de) 1995-06-14 2010-11-18 Univ California Hochaffine humane antikörper gegen tumorantigene
US20020051767A1 (en) 1995-09-13 2002-05-02 Yawen L. Chiang Cancer treatment
JPH09110722A (ja) * 1995-10-20 1997-04-28 Toray Ind Inc 抗腫瘍活性物質の腫瘍細胞内導入用イムノリポソーム及びその調製法
JP4512882B2 (ja) * 1996-02-09 2010-07-28 チェング ピー―ワン 受容体リガンドにより促進される生物活性分子の送達
US5783566A (en) * 1996-05-10 1998-07-21 California Institute Of Technology Method for increasing or decreasing transfection efficiency
US5851818A (en) * 1996-05-31 1998-12-22 Sequus Pharmaceuticals, Inc. Condensed plasmid-liposome complex for transfection
US6414139B1 (en) * 1996-09-03 2002-07-02 Imarx Therapeutics, Inc. Silicon amphiphilic compounds and the use thereof
US6030956A (en) * 1996-10-24 2000-02-29 Boulikas; Teni Combination gene therapy for human cancers
US6210707B1 (en) * 1996-11-12 2001-04-03 The Regents Of The University Of California Methods of forming protein-linked lipidic microparticles, and compositions thereof
PT956001E (pt) * 1996-11-12 2012-12-06 Univ California Preparação de formulações estáveis de complexos do tipo lípido-ácido nucleico para uma entrega eficiente in vivo
US6090800A (en) * 1997-05-06 2000-07-18 Imarx Pharmaceutical Corp. Lipid soluble steroid prodrugs
US6248721B1 (en) * 1997-04-09 2001-06-19 Lung-Ji Chang Method of using mouse model for evaluation of HIV vaccines
WO1999002647A2 (fr) * 1997-07-10 1999-01-21 Hepavec Ag Für Gentherapie Vecteurs de clonage pour preparer des adenovirus de type virus minimaux
AU1275899A (en) * 1997-10-24 1999-05-17 Megabios Corporation Methods for preparing polynucleotide transfection complexes
ATE295722T1 (de) 1997-11-19 2005-06-15 Univ Georgetown Zielgerichtete liposomen zur verabreichung von genen
US6794128B2 (en) * 1998-04-24 2004-09-21 The Regents Of The University Of California Methods of selecting internalizing antibodies
AU4090299A (en) 1998-05-20 1999-12-06 Sdg, Inc. Liposomal delivery complex
AU4089899A (en) * 1998-05-20 1999-12-06 University Of Tennessee Research Corporation, The Stable envelope proteins for retroviral, viral and liposome vectors and use in gene and drug therapy
WO2000015649A1 (fr) * 1998-09-11 2000-03-23 Thomas Jefferson University PROCEDES POUR INHIBER UNE PROLIFERATION DES CELLULES DU MUSCLE LISSE ET EMPECHER LA RESTENOSE AU MOYEN D'UN VECTEUR EXPRIMANT RB2/p130

Also Published As

Publication number Publication date
US7479276B1 (en) 2009-01-20
WO2000050008A3 (fr) 2000-12-21
EP1811036A2 (fr) 2007-07-25
CA2362550A1 (fr) 2000-08-31
JP2002537318A (ja) 2002-11-05
EP1811036B8 (fr) 2011-09-21
DE60032739T2 (de) 2007-05-24
US20090191261A1 (en) 2009-07-30
ATE511543T1 (de) 2011-06-15
CA2362550C (fr) 2010-05-11
EP1811036B1 (fr) 2011-06-01
EP1815848A1 (fr) 2007-08-08
JP4799736B2 (ja) 2011-10-26
EP1154756A2 (fr) 2001-11-21
WO2000050008A2 (fr) 2000-08-31
ES2278597T3 (es) 2007-08-16
DE60032739D1 (de) 2007-02-15
WO2000050008A9 (fr) 2002-06-27
ES2366100T3 (es) 2011-10-17
EP1154756B1 (fr) 2007-01-03
EP1811036A3 (fr) 2007-08-01
US8859274B2 (en) 2014-10-14
AU3703100A (en) 2000-09-14
US20070065432A1 (en) 2007-03-22
JP2011115167A (ja) 2011-06-16
JP5567466B2 (ja) 2014-08-06
PT1811036E (pt) 2011-07-11
ATE350012T1 (de) 2007-01-15

Similar Documents

Publication Publication Date Title
HK1106952A1 (en) Antibody fragment-targeted immunoliposomes for systemic gene delivery
Azemar et al. Recombinant antibody toxins specific for ErbB2 and EGF receptor inhibit the in vitro growth of human head and neck cancer cells and cause rapid tumor regression in vivo
Hann et al. A non-AUG translational initiation in c-myc exon 1 generates an N-terminally distinct protein whose synthesis is disrupted in Burkitt's lymphomas
BR0110610A (pt) Anticorpos isolados, imunoconjugados, cadeias de polipeptìdeos, ácido nucléico isolado, vetor, célula hospedeira, processo de produção de anticorpo ou cadeia de polipeptìdeos, método de tratamento de disfunções em mamìferos, método de indução da apoptose de uma célula cancerosa, método para matar uma célula b, método para matar uma célula que expresse um receptor de erbb e usos dos anticorpos isolados
Lammering et al. Radiation-induced activation of a common variant of EGFR confers enhanced radioresistance
EP0796277A4 (fr) Reactifs et procede de ciblage des recepteurs mutants du facteur de croissance de l'epiderme
IL174786A0 (en) Heregulin variants
RS20100555A (en) HUMAN ANTI-NGF NEUTRAL ANTIBODIES AS SELECTIVE NGF SIGNAL ROUTE INHIBITORS
EP2015758A4 (fr) Composés et procédés permettant de moduler l'expression de la protéine apob
WO2001091805A3 (fr) Composes pour le ciblage des cellules endotheliales, compositions les contenant et leurs procedes d'utilisation
UA102988C2 (ru) ВЫДЕЛЕННОЕ АНТИТЕЛО ЧЕЛОВЕКА ИЛИ ЕГО АНТИГЕН-СВЯЗЫВАЮЩАЯ ЧАСТЬ, КОТОРАЯ СВЯЗЫВАЕТ TNFα ЧЕЛОВЕКА, ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ, КОТОРАЯ ЕГО СОДЕРЖИТ, И СПОСОБ ЛЕЧЕНИЯ ЗАБОЛЕВАНИЯ, В КОТОРОМ АКТИВНОСТЬ TNFα ЯВЛЯЕТСЯ ВРЕДНОЙ
WO2001000244A3 (fr) Techniques de traitement utilisant des conjugues maytansinoides-anticorps anti-erbb
BR0314121A (pt) Composições nutricionais
NO20055209D0 (no) Peptabody for cancerbehandling
Shishido et al. Affibody-displaying bionanocapsules for specific drug delivery to HER2-expressing cancer cells
WO2006083797A3 (fr) Amelioration et protection en therapie cellulaire dans le cas de troubles neurologiques y compris la maladie de parkinson
WO2002036625A3 (fr) Polypeptides de prokineticine, et methodes et compositions associees
AU2001255260A1 (en) Macroaggregated protein conjugates as oral genetic immunization delivery agents
WO1996008274A3 (fr) Conjugues d'un facteur de croissance semblable au facteur de croissance epidermique de type hbgf, et d'agents a cible definie
WO2004037198A3 (fr) Induction de la mort de cellules tumorales provoquee par un anticorps
MXPA02006168A (es) Uso de las proteinas de transporte para el control de ciclo celular.
Jin et al. The Rab11-FIP1/RCP gene codes for multiple protein transcripts related to the plasma membrane recycling system
IL158184A0 (en) Anti-muc-1 single chain antibodies for tumor targeting
AU2092700A (en) Novel potassium channels and genes encoding these potassium channels
Gaidamakova et al. Molecular vehicle for target-mediated delivery of therapeutics and diagnostics

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20180222